Close Menu

The story has been updated to include comments from the company's conference call.

NEW YORK – Bio-Techne said on Tuesday morning that its total fiscal fourth quarter sales declined 8 percent year over year while its Diagnostics and Genomics segment was essentially flat.

For the three months ended June 30, the Minneapolis-based company reported sales of $175.8 million, down from $191.7 million a year ago. It beat the consensus Wall Street estimate of $163.9 million. Organically, sales in Q4 2020 also declined 8 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.